Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As an oncologist, Kristen Hege first encountered cancer cell therapy research in the mid-1990s. Now as a Bristol Myers Squibb executive, she oversees efforts to improve the pharma giant’s first generation of cell therapies while also building a pipeline of next-generation treatments with better features and properties.
CAR T cell therapies for cancer still pose challenges in manufacturing, safety, and the ability to address solid tumors. A panel at the World Medical Innovation Forum discussed efforts to improve CAR T as well as new approaches for the next generation of cell therapies.
A Chinese team found that DSIs help maintain the efficacy of CAR-T therapy for patients with B-ALL who relapse after transplant. The study was published on as a preprint and has not yet been peer reviewed.
Alternative strategies could be offered to children and young adults with advanced acute lymphoblastic leukemia (ALL) identified as being unlikely to respond to the expensive therapy.
The approach, which combines a chimeric antigen receptor with an RNA vaccine, showed early efficacy against advanced testicular and ovarian cancers.